IRIS PubliCatt

Criscuolo, Marianna
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.607
EU - Europa 2.343
AS - Asia 776
SA - Sud America 28
AF - Africa 16
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 4
Totale 5.784
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.595
DE - Germania 858
SE - Svezia 503
CN - Cina 396
IT - Italia 218
UA - Ucraina 184
SG - Singapore 161
IE - Irlanda 126
FR - Francia 110
PL - Polonia 110
ID - Indonesia 83
IN - India 67
FI - Finlandia 55
RU - Federazione Russa 55
GB - Regno Unito 41
TR - Turchia 22
BE - Belgio 16
NL - Olanda 16
BR - Brasile 12
JP - Giappone 12
CI - Costa d'Avorio 11
AU - Australia 10
CA - Canada 9
ES - Italia 9
IR - Iran 8
CZ - Repubblica Ceca 7
NO - Norvegia 7
TH - Thailandia 7
VN - Vietnam 7
CO - Colombia 6
CH - Svizzera 5
AT - Austria 4
CL - Cile 4
AR - Argentina 3
BG - Bulgaria 3
HU - Ungheria 3
IL - Israele 3
KR - Corea 3
MX - Messico 3
RO - Romania 3
ZA - Sudafrica 3
EU - Europa 2
GR - Grecia 2
HK - Hong Kong 2
HR - Croazia 2
MD - Moldavia 2
MY - Malesia 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
BO - Bolivia 1
DK - Danimarca 1
EC - Ecuador 1
EG - Egitto 1
IS - Islanda 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
PK - Pakistan 1
PT - Portogallo 1
RS - Serbia 1
SO - Somalia 1
UY - Uruguay 1
Totale 5.784
Salva come PNG Salva come JPEG
Città #
Chandler 559
Ashburn 171
Jacksonville 138
Dublin 120
San Mateo 112
Singapore 112
Ann Arbor 109
Warsaw 106
Dearborn 96
Woodbridge 94
Houston 93
Nanjing 93
Jakarta 81
Wilmington 79
New York 63
Fairfield 56
Chicago 52
Milan 51
Boston 45
Bremen 44
Moscow 44
Nürnberg 40
Cattolica 38
Seattle 38
Redwood City 37
Nanchang 36
Los Angeles 34
Princeton 34
Lawrence 33
Munich 27
Beijing 25
Hangzhou 23
Marseille 23
Leawood 20
Shenyang 20
Mountain View 19
Cambridge 18
Shanghai 18
Kunming 17
Brussels 16
Chatsworth 16
Redmond 16
Rome 15
Auburn Hills 14
Augusta 14
Falls Church 13
Izmir 13
Pune 13
Zhengzhou 13
Hebei 12
Abidjan 11
Boardman 11
Changsha 11
Norwalk 11
Tianjin 11
Hefei 10
Jiaxing 10
Guangzhou 9
Jinan 9
University Park 9
Lappeenranta 8
Simi Valley 8
São Paulo 8
Washington 8
Helsinki 7
Philadelphia 7
Brooklyn 6
Edinburgh 6
Enterprise 6
Hanoi 6
London 6
Bolzano 5
Fremont 5
Lanzhou 5
Bari 4
Busto Arsizio 4
Changchun 4
Costa Mesa 4
Groningen 4
Kraków 4
Medellín 4
Sydney 4
Trieste 4
Vancouver 4
Andover 3
Berlin 3
Budapest 3
Cape Town 3
Esslingen am Neckar 3
Gunzenhausen 3
Kish 3
Kocaeli 3
Madrid 3
Mcallen 3
Monmouth Junction 3
Mumbai 3
New Delhi 3
Ningbo 3
Nuremberg 3
Oslo 3
Totale 3.254
Salva come PNG Salva come JPEG
Nome #
Fanconi anemia gene variants in therapy-related myeloid neoplasms 256
PTEN/PI3K/AKT PATHWAY DYSREGULATION IN MYELODYSPLASTIC GRANULOCYTES 170
MTHFR polymorphysms in myelodysplastic syndromes and therapy-related myeloid neoplasms 135
Why methylation is not a marker predictive of response to hypomethylating agents 134
Characteristics and outcome of therapy-related myeloid neoplasms: Report from the italian network on secondary leukemias. 133
Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases 132
Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases 131
Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas. 130
SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms. 130
Impairment of PI3K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes 124
Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database 121
Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia. 119
Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma. 118
Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms 114
Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma 111
Primary plasma cell leukemia followed by testicular plasmacytoma 110
Tumor lysis syndrome: review of pathogenesis, risk factors and management of a medical emergency 107
Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms 106
Epigenetic changes in therapy-related MDS/AML 104
Similarities and differences between therapy-related and elderly acute myeloid leukemia 103
in Higher-Risk Myelodysplastic Syndromes and Low Blast Count Acute Myeloid Leukemia: Results of the BMT-AZA Prospective Study 102
Polymorphisms of detoxification and DNA repair enzymes in myelodyplastic syndromes 101
Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine 101
5-azacytidine in chronic myelomonocytic leukemia: case report and review of literature 101
Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas 99
Outcome of therapy-related myeloid neoplasms treated with azacitidine 94
Changes in the incidence of candidemia and related mortality in patients with hematologic malignancies in the last ten years. A SEIFEM 2015-B report 91
The BCL2L10 Leu21Arg variant and risk of therapy-related myeloid neoplasms and de novo myelodysplastic syndromes 88
Clonal evolution in therapy-related neoplasms 87
Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia 82
Treatment of primary plasma cell leukemia with high doses of cyclophosphamide, bortezomib, and dexamethasone followed by double autologous HSCT 82
Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study 80
Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule 77
Impairment of PI3K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes 74
SEIFEM 2017: from real life to an agreement on the use of granulocyte transfusions and colony-stimulating factors for prophylaxis and treatment of infectious complications in patients with hematologic malignant disorders 74
Transcription factors implicated in late megakaryopoiesis as markers of outcome after azacitidine and allogeneic stem cell transplantation in myelodysplastic syndrome 73
High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study 72
Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia 69
Bloodstream infections caused by Escherichia coli in onco-haematological patients: Risk factors and mortality in an Italian prospective survey 68
Aggressive Light Chain Myeloma Originating a Double Peak on Serum Electrophoresis: What's Underneath? 67
Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. 66
Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes 63
Candidaemia in haematological malignancy patients from a SEIFEM study: Epidemiological patterns according to antifungal prophylaxis 63
Rapid response of nodular CD30-positive mycosis fungoides to brentuximab vedotin 62
Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations 61
Therapy-related myeloid neoplasms: Clinical perspectives 59
Invasive aspergillosis in acute myeloid leukemia: Are we making progress in reducing mortality? 58
Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a “Gruppo Romano Mielodisplasie (GROM)” multicenter study 57
Allogeneic Transplant for Mycosis Fungoides in Patient with Wiskott-Aldrich Syndrome 57
In vitro Effect of Eltrombopag Alone and in Combination With Azacitidine on Megakaryopoiesis in Patients With Myelodysplastic Syndrome 57
SEIFEM 2017: from real life to an agreement on the use of granulocyte transfusions and colony-stimulating factors for prophylaxis and treatment of infectious complications in patients with hematologic malignant disorders 56
Risk of infectious complications in patients with chronic lymphocytic leukemia in the era of BCR inhibitors: a retrospective single institution experience 56
Risk of infectious complications in patients with chronic lymphocytic leukemia in the era of BCR inhibitors: a retrospective single institution experience 55
A population-based study on myelodysplastic syndromes in the Lazio Region (Italy), medical miscoding and 11-year mortality follow-up: The Gruppo Romano-Laziale Mielodisplasie experience of retrospective multicentric registry 53
TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS 53
A bronchoalveolar lavage-driven antimicrobial treatment improves survival in hematologic malignancy patients with detected lung infiltrates: A prospective multicenter study of the SEIFEM group 52
The validity of the fifth and the 10th Body Mass Index percentile as weight cut-offs for anorexia nervosa in adolescence: No evidence from quantitative and network investigation of psychopathology 50
Invasive aspergillosis in acute myeloid leukemia: Are we making progress in reducing mortality? 46
Extramedullary Involvement in Acute Myeloid Leukemia. A Single Center Ten Years' Experience 46
Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata 45
Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper 45
Fungaemia in haematological malignancies: SEIFEM-2015 survey 43
Isavuconazole in Hematological Patients: Results of a Real-Life Multicentre Observational Seifem Study 43
Systemic mastocytosis revisited with an emphasis on skeletal manifestations 43
Impact of invasive aspergillosis occurring during first induction therapy on outcome of acute myeloid leukaemia (SEIFEM-12B study) 42
Disseminated geosmithia argillacea infection in a patient with ph-positive acute lymphoblastic leukemia. Case report and literature review 38
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry 34
Mastocytosis: One Word for Different Diseases 31
Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study 29
Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry 19
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted 17
High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study 17
Clinical features and prognostic factors of Magnusiomyces (Saprochaete) infections in haematology. A multicentre study of SEIFEM/Fungiscope 14
In vitro effect of eltrombopag alone and in combination with azacitidine on megakaryopoiesis in patients with myelodysplastic syndrome 12
A review of prophylactic regimens to prevent invasive fungal infections in hematology patients undergoing chemotherapy or stem cell transplantation 10
Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022 10
Second Neoplasms in Italian Patients with Hairy Cell Leukemia after Treatment with Cladribine: A Multicenter Investigation and Literature Review 10
Bloodstream infections due to Gram-negative bacteria in patients with hematologic malignancies: updated epidemiology and risk factors for multidrug-resistant strains in an Italian perspective survey 7
SARS-CoV-2 Infection In Patients With Mastocytosis: An EPICOVIDEHA Report 6
The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeutic scenario of systemic mastocytosis 6
Unveiling the Hidden Burden: From EPICOVIDEHA to EPIFLUEHA, Exploring the Epidemiology of Respiratory Viral Infections in Hematological Patients 6
Totale 5.867
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.652
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.652
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020613 0 0 0 63 115 138 51 23 60 63 43 57
2020/2021637 27 51 15 46 65 82 83 18 56 53 123 18
2021/2022689 64 39 8 29 51 35 13 122 37 72 94 125
2022/20231.446 185 206 122 267 77 180 50 110 157 20 52 20
2023/2024734 37 185 27 27 29 131 60 15 11 26 90 96
2024/2025237 49 58 128 2 0 0 0 0 0 0 0 0
Totale 5.867